Aileron Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $99.19 Mil.
During the past 12 months, Aileron Therapeutics's average Total Assets Growth Rate was 19888.50% per year.
During the past 3 years, the average Total Assets Growth Rate was 227.00% per year.
During the past 5 years, the average Total Assets Growth Rate was 12.10% per year.
During the past 9 years, Aileron Therapeutics's highest 3-Year average Total Assets Growth Rate was 227.00%. The lowest was -54.60%. And the median was 36.80%.
The historical data trend for Aileron Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Aileron Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aileron Therapeutics (NAS:ALRN) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Aileron Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Aileron Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Aileron Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Aileron Therapeutics (Aileron Therapeutics) Business Description
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALRN has been successfully added to your 